Drug intelligence / Profile preview

Amikacin + Rifampicin + Ethambutol

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Oral

Overview

This combination is used to treat infections caused by mycobacteria, specifically **Mycobacterium avium** complex (MAC) and sometimes in cases of **multidrug-resistant tuberculosis (MDR-TB)**. The drugs work through different mechanisms: - **Amikacin** inhibits protein synthesis by binding to the 30S subunit of ribosomes, preventing bacterial growth. - **Rifampicin** inhibits RNA synthesis by binding to the β subunit of RNA polymerase. - **Ethambutol** inhibits arabinosyltransferases, preventing mycobacterial cell wall synthesis. The combination is synergistic, meaning it is more effective when used together than when each drug is used alone.

Other names: Combination of Amikacin, Rifampicin, and Ethambutol

Targets

EtbR (Ethambutol-regulated repressor)rpoB (DNA-directed RNA polymerase subunit beta)Bacterial RibosomeembA (Arabinosyltransferase A)

Beyond the preview

Go deeper on Amikacin + Rifampicin + Ethambutol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amikacin + Rifampicin + Ethambutol.

Explore the full profile